Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration. (3rd November 2021)

• Record Type: Journal Article
• Authors: Bai, Jane P. F.; Earp, Justin C.; Florian, Jeffry; Madabushi, Rajanikanth; Strauss, David G.; Wang, Yaning; Zhu, Hao
• Is Part Of: CPT: pharmacometrics & systems pharmacology. Volume 10:Number 12(2021)
• Page Start: 1479
• Page End: 1484
• Publication Date: 2021-11-03
• Subjects: Pharmacokinetics -- Periodicals; Pharmacology -- Periodicals; Pharmacokinetics; Periodicals; 615.05
• DOI: 10.1002/psp4.12709
• Languages: English
• ISSNs: 2163-8306

Abstract

Abstract: Quantitative systems pharmacology (QSP) has been proposed as a scientific domain that can enable efficient and informative drug development. During the past several years, there has been a notable increase in the number of regulatory submissions that contain QSP, including Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics License Applications (BLAs) to the US Food and Drug Administration. However, there has been no comprehensive characterization of the nature of these regulatory submissions regarding model details and intended applications. To address this gap, a landscape analysis of all the QSP submissions as of December 2020 was conducted. This report summarizes the (1) yearly trend of submissions, (2) proportion of submissions between INDs and NDAs/BLAs, (3) percentage distribution along the stages of drug development, (4) percentage distribution across various therapeutic areas, and (5) nature of QSP applications. In brief, QSP is increasingly applied to model and simulate both drug effectiveness and safety throughout the drug development process across disease areas.